ID

39893

Descripción

Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00928252

Link

https://clinicaltrials.gov/show/NCT00928252

Palabras clave

Versiones (1)
  1. 1/3/20 1/3/20 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

1 de marzo de 2020

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Hormone Refractory Prostate Cancer NCT00928252

Inglés

Eligibility Hormone Refractory Prostate Cancer NCT00928252

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. provision of written informed consent.
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
2. men, over 18 years of age, with histologically-confirmed diagnosis of prostate cancer
Descripción

Gender | Age | Prostate carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
UMLS CUI [3]
C0600139
3. history of treatment by complete androgen blockade for greater than 3 months prior to enrollment
Descripción

Total Androgen Blockade

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2986598
4. progressive disease evidenced by 2 consecutive rises in psa measured at least 1 week apart, with the absolute value of the latest psa > 5.0 ng/ml.
Descripción

Progressive Disease | Raised prostate specific antigen Quantity | Prostate specific antigen measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1335499
UMLS CUI [2,1]
C0178415
UMLS CUI [2,2]
C1265611
UMLS CUI [3]
C0201544
5. a rise in psa following anti-androgen drug withdrawal, above the last psa value before withdrawal.
Descripción

Raised prostate specific antigen | Status post Androgen Antagonist Withdrawal

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0178415
UMLS CUI [2,1]
C0231290
UMLS CUI [2,2]
C0002842
UMLS CUI [2,3]
C2349954
6. patient has agreed to treatment for hormone-refractory (ie. castrate-resistant) prostate cancer under supervision of a medical oncologist, urologist, radiation oncologist or nuclear medicine physician. treatments indicated for hrpc are docetaxel-, cabazitaxel-, or mitoxantrone-based chemotherapy, abiraterone, radium-223, enzalutamide, or sipulecuil-t.
Descripción

Therapeutic procedure Hormone refractory prostate cancer | Chemotherapy Docetaxel Based | Chemotherapy Cabazitaxel Based | Chemotherapy Mitoxantrone Based | abiraterone | Radium-223 | enzalutamide | sipuleucel-T

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1328504
UMLS CUI [2,1]
C0392920
UMLS CUI [2,2]
C0246415
UMLS CUI [2,3]
C1705938
UMLS CUI [3,1]
C0392920
UMLS CUI [3,2]
C2830183
UMLS CUI [3,3]
C1705938
UMLS CUI [4,1]
C0392920
UMLS CUI [4,2]
C0026259
UMLS CUI [4,3]
C1705938
UMLS CUI [5]
C0754011
UMLS CUI [6]
C0303282
UMLS CUI [7]
C3496793
UMLS CUI [8]
C1706668
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or superficial transitional cell carcinoma of the bladder.
Descripción

Cancer Other | Exception Basal cell carcinoma | Exception Superficial transitional cell carcinoma of bladder

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007117
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0279680
UMLS CUI [3,3]
C0205124
2. serious underlying medical conditions that would otherwise impair the patient's ability to undergo imaging.
Descripción

Medical condition Serious Impairing Imaging

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0221099
UMLS CUI [1,4]
C0011923
3. patient weighs over 350 lbs (due to scanner weight limit).
Descripción

High weight

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0948775
4. clinical life expectancy < 12 weeks.
Descripción

Life Expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
5. participated in other radioactive drug studies where estimated total cumulative dose within 1 year is > 0.05 sievert for whole body, active blood-forming organs, eye lens, gonads, or 0.15 sievert for other organs.
Descripción

Study Subject Participation Status | Radiopharmaceuticals Cumulative Dose per year Estimated

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2,1]
C0182638
UMLS CUI [2,2]
C2986497
UMLS CUI [2,3]
C0439508
UMLS CUI [2,4]
C0750572
6. concurrent therapy. allowed: prior or concurrent chemotherapy, but must be > 12 weeks since last treatment at enrollment; prior or concurrent hormonal therapy; prior surgery; prior or concurrent bisphosphonate; prior or concurrent receptor/biologic agent allowed if given on approved study protocol.
Descripción

Concurrent therapy allowed | Prior Chemotherapy allowed | Hormone Therapy | Prior surgery | Diphosphonates | Biological agents allowed

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0009429
UMLS CUI [1,2]
C0683607
UMLS CUI [2,1]
C1514457
UMLS CUI [2,2]
C0683607
UMLS CUI [3]
C0279025
UMLS CUI [4]
C0455610
UMLS CUI [5]
C0012544
UMLS CUI [6,1]
C0005515
UMLS CUI [6,2]
C0683607
Volver a la parte superior de la página

Similar models

Eligibility Hormone Refractory Prostate Cancer NCT00928252

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
1. provision of written informed consent.
boolean
C0021430 (UMLS CUI [1])
Gender | Age | Prostate carcinoma
Item
2. men, over 18 years of age, with histologically-confirmed diagnosis of prostate cancer
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0600139 (UMLS CUI [3])
Total Androgen Blockade
Item
3. history of treatment by complete androgen blockade for greater than 3 months prior to enrollment
boolean
C2986598 (UMLS CUI [1])
Progressive Disease | Raised prostate specific antigen Quantity | Prostate specific antigen measurement
Item
4. progressive disease evidenced by 2 consecutive rises in psa measured at least 1 week apart, with the absolute value of the latest psa > 5.0 ng/ml.
boolean
C1335499 (UMLS CUI [1])
C0178415 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0201544 (UMLS CUI [3])
Raised prostate specific antigen | Status post Androgen Antagonist Withdrawal
Item
5. a rise in psa following anti-androgen drug withdrawal, above the last psa value before withdrawal.
boolean
C0178415 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C0002842 (UMLS CUI [2,2])
C2349954 (UMLS CUI [2,3])
Therapeutic procedure Hormone refractory prostate cancer | Chemotherapy Docetaxel Based | Chemotherapy Cabazitaxel Based | Chemotherapy Mitoxantrone Based | abiraterone | Radium-223 | enzalutamide | sipuleucel-T
Item
6. patient has agreed to treatment for hormone-refractory (ie. castrate-resistant) prostate cancer under supervision of a medical oncologist, urologist, radiation oncologist or nuclear medicine physician. treatments indicated for hrpc are docetaxel-, cabazitaxel-, or mitoxantrone-based chemotherapy, abiraterone, radium-223, enzalutamide, or sipulecuil-t.
boolean
C0087111 (UMLS CUI [1,1])
C1328504 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2,1])
C0246415 (UMLS CUI [2,2])
C1705938 (UMLS CUI [2,3])
C0392920 (UMLS CUI [3,1])
C2830183 (UMLS CUI [3,2])
C1705938 (UMLS CUI [3,3])
C0392920 (UMLS CUI [4,1])
C0026259 (UMLS CUI [4,2])
C1705938 (UMLS CUI [4,3])
C0754011 (UMLS CUI [5])
C0303282 (UMLS CUI [6])
C3496793 (UMLS CUI [7])
C1706668 (UMLS CUI [8])
Item Group
C0680251 (UMLS CUI)
Cancer Other | Exception Basal cell carcinoma | Exception Superficial transitional cell carcinoma of bladder
Item
1. other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or superficial transitional cell carcinoma of the bladder.
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0279680 (UMLS CUI [3,2])
C0205124 (UMLS CUI [3,3])
Medical condition Serious Impairing Imaging
Item
2. serious underlying medical conditions that would otherwise impair the patient's ability to undergo imaging.
boolean
C3843040 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0221099 (UMLS CUI [1,3])
C0011923 (UMLS CUI [1,4])
High weight
Item
3. patient weighs over 350 lbs (due to scanner weight limit).
boolean
C0948775 (UMLS CUI [1])
Life Expectancy
Item
4. clinical life expectancy < 12 weeks.
boolean
C0023671 (UMLS CUI [1])
Study Subject Participation Status | Radiopharmaceuticals Cumulative Dose per year Estimated
Item
5. participated in other radioactive drug studies where estimated total cumulative dose within 1 year is > 0.05 sievert for whole body, active blood-forming organs, eye lens, gonads, or 0.15 sievert for other organs.
boolean
C2348568 (UMLS CUI [1])
C0182638 (UMLS CUI [2,1])
C2986497 (UMLS CUI [2,2])
C0439508 (UMLS CUI [2,3])
C0750572 (UMLS CUI [2,4])
Concurrent therapy allowed | Prior Chemotherapy allowed | Hormone Therapy | Prior surgery | Diphosphonates | Biological agents allowed
Item
6. concurrent therapy. allowed: prior or concurrent chemotherapy, but must be > 12 weeks since last treatment at enrollment; prior or concurrent hormonal therapy; prior surgery; prior or concurrent bisphosphonate; prior or concurrent receptor/biologic agent allowed if given on approved study protocol.
boolean
C0009429 (UMLS CUI [1,1])
C0683607 (UMLS CUI [1,2])
C1514457 (UMLS CUI [2,1])
C0683607 (UMLS CUI [2,2])
C0279025 (UMLS CUI [3])
C0455610 (UMLS CUI [4])
C0012544 (UMLS CUI [5])
C0005515 (UMLS CUI [6,1])
C0683607 (UMLS CUI [6,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial